PARP Inhibitor Treatment in Ovarian and Breast Cancer

[1] Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (12) : 2063 - 2070

[2] PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) : 17860 - 17868

[3] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J]. LANCET, 2010, 376 (9737) : 245 - 251

[4] Baldwin RL, 2000, CANCER RES, V60, P5329

[5] Making the best of PARP inhibitors in ovarian cancer [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) : 508 - 519

[6] BRCA1 and BRCA2 mutations in a population-based study of male breast cancer -: art. no. R2 [J]. BREAST CANCER RESEARCH, 2002, 4 (01) : R2

[7] Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair [J]. PLOS GENETICS, 2008, 4 (06)

[8] Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage [J]. CARCINOGENESIS, 1999, 20 (02) : 199 - 203

[9] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J]. NATURE, 2005, 434 (7035) : 913 - 917

[10] PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination [J]. EMBO JOURNAL, 2009, 28 (17) : 2601 - 2615

[1] Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (12) : 2063 - 2070

[2] PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) : 17860 - 17868

[3] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J]. LANCET, 2010, 376 (9737) : 245 - 251

[4] Baldwin RL, 2000, CANCER RES, V60, P5329

[5] Making the best of PARP inhibitors in ovarian cancer [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) : 508 - 519

[6] BRCA1 and BRCA2 mutations in a population-based study of male breast cancer -: art. no. R2 [J]. BREAST CANCER RESEARCH, 2002, 4 (01) : R2

[7] Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair [J]. PLOS GENETICS, 2008, 4 (06)

[8] Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage [J]. CARCINOGENESIS, 1999, 20 (02) : 199 - 203

[9] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J]. NATURE, 2005, 434 (7035) : 913 - 917

[10] PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination [J]. EMBO JOURNAL, 2009, 28 (17) : 2601 - 2615